Report center

医药生物行业深度报告：ADC药物，创新前行、出海扬帆-20231108-华金证券

u ADC创新发展加速，行业进入高速发展期。ADC作为新兴大分子靶向药物，具有相较于单药抗体、化疗等疗法的临床优势；尤其DS-8201在乳腺癌领域实现突破后更是激发全球ADC研发热情，且ADC联合疗法前景广阔。目前全球已有15款ADC药物获批上市，在研管线高达900余项，全球ADC市场有望以30.0%的高复合增速由2022年79亿美元增至2030年647亿美元；国内ADC处于刚起步阶段，相信未来3

No subject companies

Publishers

华金证券 View content →

Suggested next hops

Ranked by edge type and evidence strength (max 5). Prefer these over scrolling the full lists.

1华金证券Published by or linked to this institution1

Ask about this report neighborhood Read full report →

No related industries

No related reports

← Back to knowledge graph